Results 181 to 190 of about 25,878 (248)

Synthesis of 1,2,4-Oxadiazin-5(6H)-One Derivatives and Their Biological Investigation as Monoamine Oxidase Inhibitors. [PDF]

Molecules
Presnukhina SI, Kotlyarova VD, Shetnev AA, Baykov SV, Turmanov R, Appazov N, Zhapparbergenov R, Zhussupova L, Togyzbayeva N, Cloete SJ, Korsakov MK, Boyarskiy VP, Petzer A, Petzer JP.   +13 more
europepmc   +1 more source

Droperidol and Monoamine-oxidase Inhibitors [PDF]

BMJ, 1966
openaire   +2 more sources

Recent advances in Parkinson\u27s disease therapy: use of monoamine oxidase inhibitors.

, 2005
Monoamine oxidase inhibitors inhibit dopamine metabolism and are therefore effective in treating Parkinson\u27s disease, a condition associated with progressive striatal dopamine deficiency secondary to degeneration of dopaminergic neurons in the ...
Burgut, F Tuna, Schumacher, H Christian, Henchcliffe, Claire   +2 more
core  

Comparison of effectiveness and side effects of selegiline transdermal system versus oral monoamine oxidase inhibitors and tricyclic antidepressants for treatment-resistant depression. [PDF]

J Affect Disord
Kim TT, Xu C, Amsterdam JD.
europepmc   +1 more source

Enhancing Dopamine Accumulation in Secretory Vesicles of PC12 Cells: Mechanisms, Applications and Limitations

Journal of Neurochemistry, Volume 170, Issue 6, June 2026.
Schematic representation of a large dense‐core vesicle in PC12 cells highlighting its main molecular organization. The diagram illustrates the presence of membrane transporters, proton pumps and intravesicular matrix proteins that establish the electrochemical gradients required for neurotransmitter uptake, vesicle acidification and efficient storage ...
Noemi Socas‐Pérez, Ricado Borges, José David Machado   +2 more
wiley   +1 more source

Design, Synthesis, and Biological Effect Studies of Novel Benzofuran-Thiazolylhydrazone Derivatives as Monoamine Oxidase Inhibitors. [PDF]

ACS Omega
Osmani Ye D, Sağlik BN, Levent S, Çevi K UA, Ilgin S, Yurttaş L, Özkay Y, Karaburun AC, Kaplancikli ZA, Gundogdu-Karaburun N.   +9 more
europepmc   +1 more source

Co‐pathologies and biological processes beyond amyloid‐beta and tau in people with Alzheimer's disease: Evidence from clinical cohort studies

Journal of Internal Medicine, Volume 299, Issue 6, Page 694-710, June 2026.
Abstract Alzheimer's disease (AD) is neuropathologically defined by amyloid‐beta (Aβ) plaques and tau neurofibrillary tangles. However, co‐pathologies and other pathobiological processes are involved in the pathogenesis of AD, contributing to neurodegeneration and clinical symptoms.
Daniel Ferreira, Tomasz Chmiela, Maria Eriksdotter, Clifford R. Jack Jr., Grégoria Kalpouzos, Anna Marseglia, Patrizia Mecocci, Agneta Nordberg, Dorota Religa, Eric Westman   +9 more
wiley   +1 more source

<i>In Vitro</i> and <i>In Silico</i> ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases. [PDF]

ACS Chem Neurosci, 2020
Więckowska A, Szałaj N, Góral I, Bucki A, Latacz G, Kiec-Kononowicz K, Bautista-Aguilera ÒM, Romero A, Ramos E, Egea J, Farré Alíns V, González-Rodríguez Á, López-Muñoz F, Chioua M, Marco-Contelles J.   +14 more
europepmc   +1 more source

Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. [PDF]

RSC Med Chem, 2020
Wang XB, Yin FC, Huang M, Jiang N, Lan JS, Kong LY.   +5 more
europepmc   +1 more source

Correction: Isatin-based benzyloxybenzene derivatives as monoamine oxidase inhibitors with neuroprotective effect targeting neurodegenerative disease treatment. [PDF]

RSC Adv
Benny F, Oh JM, Kumar S, Abdelgawad MA, Ghoneim MM, Abdel-Bakky MS, Kukerti N, Jose J, Kim H, Mathew B.   +9 more
europepmc   +1 more source